Sanofi Acquires Dynavax, Ending Public Listing and Transferring Vaccine Upside to Group

Sanofi has completed its acquisition of Dynavax Technologies, delisting DVAX from Nasdaq and removing it from major stock indices. The deal triggered changes to Dynavax's board and executive leadership team. Dynavax is now fully owned by Sanofi, shifting its vaccine upside to the group. Former DVAX holders must redeploy their cash payout into other opportunities or into Sanofi for continued exposure to its assets.